Gastroenterology

Nurses Can Counter Nocebo Effect in Biosimilar Switching

January 27th 2021

By Tony Hagen

The study of originator infliximab and SB2 used nurses as the first point of contact when educating patients, relying partly on patient trust in these health care professionals.

China Pulls Out Stops for Biosimilar Development

January 25th 2021

By Tony Hagen

Article

It took Henlius years to get a rituximab biosimilar approved in China. Now, that process could be cut in half, owing to significant regulatory reforms.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18th 2021

By Tony Hagen

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.

With New Policy, CMS Promises to Exit "Stone Age" of Health Information

January 15th 2021

By Tony Hagen

Article

CMS looks to speed up health information transfer by putting faxes in the past. It also aims to set deadlines for payers to respond to prior authorization requests.

Infliximab Biosimilar Switching Study Yields Evidence of Safety, Efficacy

January 14th 2021

By Deana Ferreri, PhD

Article

A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.

Economists Probe Cost-Effectiveness of Biosimilars

January 7th 2021

By Tony Hagen

Article

Authors of a review found that biosimilar uptake and market share are not in themselves sufficient to establish whether these agents will lead to savings.

Adalimumab Biosimilars Face Product Obsolescence Before Launch

January 6th 2021

By Tony Hagen

Article

Product differentiation by concentration is a threat to the multiple adalimumab biosimilars approved but not yet launched.

Investigators Chart ABP 980 Biosimilar Uptake in European Clinics

January 4th 2021

By Tony Hagen

Article

Among patients treated for metastatic breast cancer, 40% switched to ABP 980.

Amgen's Bourdon Discusses Riabni Rollout in the United States

December 23rd 2020

By Tony Hagen

Article

Christophe Bourdon, senior vice president and general manager of US Oncology for Amgen, discussed the development and marketing plan for the company's newly approved rituximab biosimilar.

Sandoz Canada Gains Marketing Approval for Adalimumab Biosimilar

December 18th 2020

By Tony Hagen

Article

The Canada Health approval for Hyrimoz will be followed by a launch in February 2021, Sandoz Canada said.